Hamburg, Germany, and Oxford, UK, 07.06.2005
Evotec OAI AG (Frankfurt Stock Exchange: EVT, TecDAX 30) announces that at the annual shareholder meeting today the Company's shareholders approved the following agenda items which are of high strategic importance to Evotec OAI:

A capital increase of 10 million shares at an issue price of 2.72 Euro to fuel the expansion of Evotec's CNS pipeline. Existing shareholders have pre-emption rights which may be exercised from 10 June to 23 June. The capital increase is guaranteed by a group of investors who have committed to take up shares not signed for by Evotec OAI shareholders.
The re-election of Mary Tanner and the appointment of Dr. Hubert Birner, Dr. Peter Fellner and Dr. Alfred Oberholz to the Evotec OAI Supervisory Board (see press release of 6 May 2005).

In addition to the confirmation of the capital increase and the appointments to the Supervisory Board, all other resolutions were passed with more than 99% at the meeting which took place in Hamburg. A total of 51% of the shareholders' equity was represented.
 
The AGM also decided to change the Company's name from Evotec OAI AG to Evotec AG. Following the integration of Evotec Neurosciences the Company wants to reflect the growing emphasis of proprietary drug development in its business model and have a single "new" name which stands for both parts of its business.
 

Contact: Anne Hennecke, Director, Investor Relations & Corporate Communications, Phone: +49-40-56081-286, anne.hennecke@evotecoai.com
Contact: Anne Hennecke, Director, Investor Relations & Corporate Communications, Phone: +49-40-56081-286, anne.hennecke@evotecoai.com